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Abstract
SIAH proteins are the human members of an highly conserved family of E3 ubiquitin ligases. Several data suggest
that SIAH proteins may have a role in tumor suppression and apoptosis. Previously, we reported that SIAH-1
induces the degradation of Kid (KIF22), a chromokinesin protein implicated in the normal progression of mitosis
and meiosis, by the ubiquitin proteasome pathway. In human breast cancer cells stably transfected with SIAH-1,
Kid/KIF22 protein level was markedly reduced whereas, the Kid/KIF22 mRNA level was increased. This interaction
has been further elucidated through analyzing SIAH and Kid/KIF22 expression in both paired normal and tumor tis-
sues and cell lines. It was observed that SIAH-1 protein is widely expressed in different normal tissues, and in cells
lines but showing some differences in western blotting profiles. Immunofluorescence microscopy shows that the
intracellular distribution of SIAH-1 and Kid/KIF22 appears to be modified in human tumor tissues compared to nor-
mal controls. When mRNA expression of SIAH-1 and Kid/KIF22 was analyzed by real-time PCR in normal and cancer
breast tissues from the same patient, a large variation in the number of mRNA copies was detected between the
different samples. In most cases, SIAH-1 mRNA is decreased in tumor tissues compared to their normal counter-
parts. Interestingly, in all breast tumor tissues analyzed, variations in the Kid/KIF22 mRNA levels mirrored those seen
with SIAH-1 mRNAs. This concerted variation of SIAH-1 and Kid/KIF22 messengers suggests the existence of an
additional level of control than the previously described protein-protein interaction and protein stability regulation.
Our observations also underline the need to re-evaluate the results of gene expression obtained by qRT-PCR and
relate it to the protein expression and cellular localization when matched normal and tumoral tissues are analyzed.
Introduction
SIAH-1 and SIAH-2 are human homologues of the Dro-
sophila seven in absentia (sina) gene [1]. E3 ligase activ-
ity is the best characterized function of the family of
SIAHs proteins [2,3]. SIAH proteins contain an N-term-
inal RING domain that binds E2 proteins and a C-term-
inal substrate binding domain that interacts with their
target proteins, tagging them with Ubiquitin, thereby
targetting their degradation by the ubiquitin-proteasome
pathway [2-4]. The human SIAH-1 protein is 282 amino
acids long, and was found to oligomerize via its C-term-
inal sequences [5,2]. The protein structure also contains
two zinc finger cytokine-rich domains and shares 77%
identity with SIAH-2 [5].
Numerous substrates targeted for degradation by
SIAH proteins have been reported; examples include
netrin-1 receptor/deleted in colorectal cancer (DCC) [6],
the nuclear receptor co-repressor (N-CoR) [7], the tran-
scriptional activator BOB.1/OBF.1 [8,9], c-Myb [10], Kid
[3] and CtIP [11]. RING finger proteins have also been
shown to regulate their own stability through proteaso-
mal degradation [2].
Interestingly, not all SIAH-binding proteins are targets
of SIAH-mediated degradation, as it occurs for a-tubulin
[3], Vav [12], BAG1 [13] and others proteins [14]. SIAH-
1 is also implicated in GAPDH transport to the nucleus
in a novel cell death cascade, suggesting that SIAH pro-
teins may play additional roles in cell biology [15].
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teins are widely expressed but at different levels in sev-
eral normal and neoplasic human tissues [5,16]. SIAH-1
mRNA was found highly expressed in placenta, skeletal
muscle and testis and also in some cell lines, however,
there is a paucity of data concerning endogenous SIAH-
1 protein expression in human cells and tissues [17].
Our previous observations led us to propose that
SIAH-1 could have a role in tumor suppression and
apoptosis [5,17,18]. In fact, the murine SIAH-1 was
identified as a p53 inducible gene, which is up-regulated
during the physiological program of cell death [19]. The
human SIAH-1 is activated during tumor suppression
and apoptosis, notably during physiological apoptosis
occurring in the intestinal epithelium [17]. We also
reported that over-expression of SIAH-1 in the epithelial
breast cancer cell line MCF-7 blocked cellular growth by
altering the mitotic process, predominantly during
nuclei separation and cytokinesis, leading to multinu-
cleated giant cell formation and tubulin spindle disorga-
nization [17].
In order to elucidate the role of SIAH-1 in the cell
and the mechanisms by which SIAH-1 interferes with
the mitotic process, we previously searched for SIAH-1-
interacting proteins using the yeast two-hybrid system
[3]. Amongst other proteins, we identified Kid (KIF22),
a chromosome and microtubule binding-protein impli-
cated in chromosomal positioning and segregation dur-
ing cell division [20,21]. We showed a clear regulatory
link between both proteins since SIAH-1 was involved
in the degradation of Kid/KIF22 via the ubiquitin pro-
teasome pathway [3]. Further evidence implicating
SIAH-1 in tumor suppression was shown to be related
to its role in the regulation of b-catenin [22] and
hypoxia-inducible factor 1a (Hif-1a) [23,24].
Despite these efforts, the role of SIAH-1 as a tumor
suppressor remains controversial since many efforts to
identify putative mutations associated with tumoral pro-
cesses have been almost unsuccessful. Medhioub et al.
[25] searched for somatic mutations in different human
tumors and Matsuo et al. [26] analyzed human hepato-
cellular carcinomas (HCCs); both authors failed to
detect any somatic mutations in SIAH-1. In recent
works, Kim et al. [27] found two missense mutations in
the SIAH-1 gene in gastric cancer and Brauckhoff et al.
[28] observed a reduced expression of SIAH-1 in HCCs.
Therefore, these few studies undertaken to establish a
correlation between changes either in the sequence or
expression of SIAH-1 with tumoral processes have been
inconclusive. This study has attempted to further our
understanding by analyzing mRNA and protein expres-
sion of SIAH-1 and it’s substrate Kid/KIF22, in both
normal and tumor tissues. The results suggest that regu-
lation of the stability for these two interacting proteins
could be complemented by an additional regulation of
their mRNA levels.
Materials and methods
Patients and tissue samples
Breast cancer tissues and corresponding non-cancerous
breast tissues were obtained after informed consent
from patients who underwent breast resection in hospi-
tals from Montevideo (Uruguay), between 2000 and
2004. The study included 50 post menopause females
aged between 42 and 90 years with a median age of 66
years. The samples were anonymized before the study.
A pathologist dissected tissue samples from surgical spe-
cimens and confirm quality of tissues microscopically.
Cancerous and non-cancerous tissues were immediately
frozen and stored at -80°C until analysis.
Antibodies
Polyclonal antibodies against an N-terminal peptide of
SIAH-1 produced in chicken were used as previously
described [17]. Polyclonal antibodies against Kid/KIF22
were produced in rabbit with purified GST-Kid/KIF22
protein (Agrobio, France).
RNA extraction and cDNA synthesis
Total RNA from frozen tissues were extracted with Tri-
zol Reagent (Invitrogen) following manufacturer’s
instructions. The quality of RNA was analyzed by elec-
trophoresis on agarose gels stained with ethidium bro-
mide. One microgram of total RNA was reverse-
transcribed in a final volume of 20 μL containing 1 ×
reverse transcriptase buffer (Invitrogen), 1.25 mM
dNTPs (Quantum Biotechnologies) 10 mM DTT (Invi-
trogen), 5 ng/μL random hexamers (Roche), 1 U/μL
RNAse inhibitor and 10 U/μL M-MLV reverse tran-
scriptase (Invitrogen). The reaction mix was incubated
at 42°C for 1 h, the reverse transcriptase was inactivated
by 5 min incubation at 95°C. cDNA was stored at -20°C
until analysis.
Quantitative Real-Time PCR
To evaluate the relative expression of SIAH-1 and Kid/
KIF22, quantitative real time PCR was performed using
a LightCycler (Roche Diagnostics). Primers and fluores-
cent TaqMan probes were designed using Primer
Express software (PE Applied Biosystems) and are
shown in Table 1. RT-PCR reaction were carried out
with an aliquot of 2 μL of the resulting cDNA in a final
volume of 20 μL, using 100 nM of the specific hydro-
lyzed probe, 200 nM of the probe flanking appropriate
primer pairs, and 18 μL of LC fast start DNA master
mix (Roche). After 10 min at 95°C, 45 cycles of 5 s at
95°C and 10 s at 60°C were performed. Standards were
prepared from total normal RNA, amplified by RT-PCR
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were then calculated by setting their crossing points to
the standard curve. The expression levels of SIAHs and
Kid/KIF22 were normalized using the expression of the
housekeeping gene b2 microglobulin as a reference. All
experiments were performed in duplicate. All coeffi-
cients of variation of Cp values were < 1%.
Western blotting
Cell lysates from 14 human cell lines and 10 normal
human tissues were obtained from Imgenex (Clinis-
ciences, France). 10 μg of protein lysates were resolved
by reducing 12% SDS-PAGE and transferred to nitrocel-
lulose membranes Hybond-C (Amersham). After elec-
trophoresis, protein transfer was verified by Ponceau
staining. The nitrocellulose membranes were probed
with antibodies anti-SIAH-1 and anti-Kid/KIF22 (both
diluted 1:1000) followed by horseradish peroxidase-
coupled secondary antibodies (Jackson ImmunoResearch
Laboratories, Inc.) anti-chicken IgG (diluted 1:2000) or
anti-rabbit IgG (diluted 1:2500) and detected using a
chemiluminescence-based detection system (ECL,
Amersham).
Immunofluorescence staining
Paraffined tissue array slides containing 20 normal and
19 matched malignant human tumor tissues, or 25 can-
cerous and 4 normal breast human tissues were
obtained from Imgenex (Clinisciences, France), and pro-
cessed as per manufacturer recommendations. Breast
tumors and normal surrounding tissues from the same
patients were obtained by sectioning frozen tissues. The
slides were fixed in 2% paraformaldehyde (PFA) for 10
min at room temperature (RT) and washed in PBS six
times. Nonspecific protein binding was blocked by incu-
bation in a PBS solution containing 3% BSA, 0.1% sapo-
nin for 2 h at RT. Slides were then incubated overnight
with primary antibody diluted in 0.3% BSA, 0.1% sapo-
n i ni nP B Sa t4 ° C .A f t e rs i xw a s h e sw i t hP B S ,s t a i n i n g
was revealed using a Rhodamine Red-X-conjugated sec-
ondary antibody for SIAH-1 and FITC-conjugated sec-
ondary antibody for Kid/KIF22 (Jackson Labs). Slides
were subsequently analysed using a Zeiss epifluores-
cence microscope equipped with a cooled three-charged
coupled device (3CCD) camera (Lhesa, France), triple
band pass filter and a high numerical aperture lens
(40 × 1.3 NA and 100 × 1.3 NA).
Results
Analysis of SIAH-1 in human tissues and cell lines extracts
The expression of SIAH-1 in a variety of human tissues
and human derived cell lines was explored by western
blotting using SIAH-1 anti-sera (previously described
[17]), (Figure 1). Two major bands with an apparent
MW of ~35 kDa and ~70 kDa were detected in human
brain, heart, small intestine, Kidney and pancreas
extracts. In contrast, no bands were evident in human
lung, testis and spleen extracts (Figure 1a). The smooth
muscle extract showed only the minor band of ~35 kDa.
In addition, an extra band of ~52 kDa was detected in
brain, liver and pancreas extracts. Besides the two prin-
cipal bands, additional bands of higher molecular weight
showing a ladder pattern were detected in small intes-
tine and pancreas extracts. This profile is characteristic
of polyubiquitinated proteins. In the cell lines homoge-
nates we also found two main bands corresponding to
the ~35 kDa and the ~70 kDa polypeptides (Figure 1b).
In addition, other bands were detected in some cell
lines like A375, A549 and HL60.
SIAH-1 and Kid/KIF22 protein expression in cancerous
and non-cancerous tissues
In order to further characterize SIAH-1 and Kid/KIF22
expression in cancerous and non-cancerous tissues, pro-
teins were analyzed at the cellular level, by fluorescence
microscopy. Firstly SIAH-1 staining on tissue array
slides containing normal and matched malignant human
tissues was performed. Comparing SIAH-1 expression in
these tissues, it was shownt h a ti nt h en o r m a lc e l l so f
most tissues the protein was predominantly expressed in
the cytoplasm, showing a punctuate staining pattern. In
normal breast tissues, acinar cells show a very strong
label compared to surrounding cells (Figures 2a). In
breast tumor tissues SIAH-1 expression was less intense
and more heterogeneous showing a more diffuse pat-
tern, and nuclei were also frequently stained (Figure 2d).
In normal liver cells, SIAH-1 expression was also high
and the expression was similar in all cells (Figure 2b).
Table 1 Primers and TaqMan probes used to quantify mRNA expression of SIAH-1, Kid/KIF22 and b2 microglobulin.
Gen PCR
Product (bp)
Primers TaqMan Probe
SIAH-1 75 5’-GCTAAATGGTCATAGGCGACG-3’
5’-ATGGCTGTTGCAATTCCTTCAT-3’
5’-TTGACTTGGGAAGCGACTCCTCGATCTA-3’
Kid/KIF22 76 5’-CGGCCTTTTACCAATGAGAGC-3’
5’-GACCAAGCAATTCTTTCTGAGACA-3’
5’-CAGCCTCATGCCTTGGGACCTGTTAAG-3’
b2 microglobulin 67 5’-CGCTCCGTGGCCTTAGC-3’
5’-GAGTACGCTGGATAGCCTCCA-3’
5’-TGCTCGCGCTACTCTCTCTTTCTG-3’
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Figure 1 Physiological expression of SIAH-1 protein. Polyclonal chicken anti-SIAH-1 antibodies was used to detect SIAH-1 protein.
(a) Immunoblot of protein extracts from different human tissues. (b) Immunoblot of different human cell lines derived from cervical carcinoma
(HeLa), T-cell leukemia (Jurkat), Burkitt’s lymphoma (Daudi), embryonal Kidney (293), rhabdomyoscarcoma (Rh30), melanoma (A375), glioblastoma
(T98G), colon carcinoma (HCT-116), larynx carcinoma (Hep-2), lung carcinoma (A549), endothelial normal cells (HUVEC), breast adenocarcinoma
(MCF-7), promyelocytic leukemia (HL-60) and bone marrow neuroblastoma (SK-N-SH).
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geneity in SIAH-1 protein expression with some cells
expressing high levels whereas in the majority there was
no detectable expression (Figure 2e). Other analyzed
organs displayed a less systematic variation between
normal and tumor tissues (e.g. lung), however all the
tumoural specimens displayed the heterogenous pattern,
with groups of tumor cells expressing very high levels of
SIAH-1 and others without any detectable expression
(Figure 2f). In addition, very low levels of SIAH-1 pro-
tein were detected in some normal tissues (e.g. lung,
Figure 2c) and is consistent with the Western blot find-
ings in Figure 1a.
SIAH-1 and Kid/KIF22 protein expression were com-
pared in normal and tumor breast tissues obtained from
t h es a m ep a t i e n t( F i g u r e3 ) .T h es t a i n i n gw i t hS I A H - 1
in normal tissues revealed a similar punctuate pattern as
described above, while in tumor tissues the expression
was diffuse and was both cytoplasmic and nuclear (Fig-
ure 3a, d). In the case of Kid/KIF22, the cellular labeling
was also different between each normal tissue sample
and its tumor counterpart (Figure 3b, e). In normal
cells, the protein was mostly cytoplasmic, localized in
perinuclear areas (Figure 3b), while in malignant cells
the expression was more diffuse (nuclear and cytoplas-
mic), with a punctuate pattern observed mostly in nuclei
(Figure 3e).
SIAH-1 and Kid/KIF22 mRNA expression in normal and
tumor tissues
We have previously analyzed the effect of SIAH-1 on
Kid/KIF22 protein expression in MCF-7 cells stably
transfected with SIAH-1 cDNA. The level of endogen-
ous Kid/KIF22 protein was markedly reduced in clones
overexpressing SIAH-1, whereas by Northern blot analy-
sis we did not observe a reduction in Kid/KIF22 mRNA
synthesis but rather an increase [3].
To further the relationship of Kid/KIF22 and SIAH-1
mRNA expression in physiological conditions and in
tumoral processes, a quantitative RT-PCR of SIAH-1
and Kid/KIF22, in paired normal and cancerous breast
tissues from the same patient was ran. Overall, samples
were obtained from 50 patients, however mRNA quanti-
fication of coupled samples was only possible for 25 due
to the low yield or poor quality of the extracted RNA
from some of the tissues. The mRNAs were normalized
related to the number of mRNA copies of the house-
keeping gene b2 microglobulin. Important variations in
the number of mRNAs copies amongst the samples
were observed. Representative results from some of stu-
died patients are showed in Figure 4. The number of
SIAH1 copies extends from 1,48 to 61,6 × 10
3 (with a
median of 17,41 × 10
3) for normal tissues and from 0.35
×1 0
3 to 52,04 × 10
3 copies (with a median of 5,73 ×
10
3) in tumoral tissues. Comparison of the paired nor-
mal and tumoral samples from patients, revealed that in
19 of 25 cases (76%), the level of SIAH-1 mRNA was
reduced in breast cancer tissues compared to their cor-
responding non-cancerous breast tissue. In some of the
samples the mRNA expression was remarkably reduced,
more than 90% and in most cases the decrease was
higher than 50%.
Interestingly, the changes in the levels of Kid/KIF22
mRNA mirrored that of SIAH-1 in all of the patients.
Kid/KIF22 mRNA levels were decreased in all tumors in
which SIAH-1 mRNA was decreased and vice versa
(Figure 4). Moreover, except for one sample, the num-
ber of Kid/KIF22 mRNA copies was consistently higher
than the SIAH-1 mRNA copies in all normal tissues
(with a median of 19,2 × 10
3)c o m p a r e dt ot h e i rc o r r e -
sponding paired tumor tissues (median of 16,5 × 10
3).
Discussion
In this study, we compared SIAH-1 mRNA and protein
expression levels in normal and tumor tissues and cell
lines. SIAH-1 protein was found to be widely expressed
in human cell lines and tissues. In non-proliferating tis-
sues that express higher levels of SIAH-1 mRNA, a sin-
gle band of the expected MW is detectable (muscle), or
it represents almost the totality of the detected protein
(brain). In other tissues and majority of cells lines a sec-
ond band appears whose molecular weight is approxi-
mately the double of the first one. Although it is known
that SIAH-1 forms stable homodimers [2,3,29], under
reducing conditions used in SDS-PAGE a single band
would be expected. The additional bands observed in
Figure 1 could correspond to post-translational modifi-
cations, or to transcriptional or splicing variants of
SIAH-1. Indeed, human SIAH-1 mRNA is 2.3 kb but an
additional transcript of 2.5 kb was shown in placenta
[5]; in MCF-7 cells, a SIAH-1 variant that encodes a 298
amino acid protein designated SIAH-1L was reported
[30] whereas another variant named SIAH-1S encoding
a 195 amino acid protein was detected in breast, Kidney
and esophagus cancer tissues [31].
The broad tissue distribution of SIAH-1 suggests that
it may play a relevant cellular role; however, high levels
and splicing variants of SIAH-1 in particular tissues may
represent sites of critical gene function or relate to phy-
siological/pathological situations. Consistent with this,
important differences in SIAH-1 expression were
observed amongst cell lines and tissues. Interestingly, in
some tissues such as the small intestine, other bands of
high molecular weight appear suggesting the presence of
polyubiquitinated forms of SIAH-1. This observation is
consistent with previous reports, since SIAH-1 was
shown to be auto-ubiquitinated and degraded via the
proteasome pathway [2,3] and we showed a strong
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Page 5 of 10SIAH-1 expression in the cells at the apical of the intes-
tine villi, where cells are differentiated and die by apop-
tosis [17].
By fluorescence microscopy, SIAH-1 was shown to be
highly expressed in the cytoplasm of normal breast cells,
with a punctuate pattern. In tumor tissues however, it
appeared as a more uniform distribution, localized to
both the cytoplasm and nucleus. Similarly, whereas in
normal liver the expression was high and homogeneous
among cells, tumor tissues showed significant heteroge-
neity with some cells expressing high levels of SIAH
whilst being undetectable in others. Our results are
consistent with previous reports on the cellular localiza-
tion of SIAH-1; The punctuate pattern was described
for endogenous SIAH-1 in human intestine and MCF-7
cell line [17] and GFP-SIAH-1 transfected cells [11], and
was associated with the presence of this protein on early
endosomes in PC12 cells [32]. Some authors have
observed that in transfected cell lines overexpressing
SIAH-1, the protein was localized predominantly in the
cytoplasm [6,16,33], whilst others reported that it was
also present in the nucleus [13] and particularly asso-
ciated to the nuclear matrix [17]. It is interesting to
note that regardless if SIAH-1 was expressed
a
e b
d
c f
Normal Tumoral
Figure 2 SIAH-1 protein expression in normal and tumor tissues. Normal breast (a), liver (b) and lung (c) normal tissues and its respective
tumor counterpart from the same patient (d), (e) and (f) are showed. Paraffined tissues were stained with anti-SIAH-1 antibody, and detected
with a secondary antibody conjugated to Rhodamine Red-X. Cells were counterstained with DioC6 (green) to mark the ER, cellular membranes,
and mitochondria.
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Figure 3 Expression of SIAH-1 and Kid/KIF22 in paired normal and tumor breast tissues from the same patient. Normal (a, b and c) and
tumor (d, e and f) frozen breast tissue from the same patient are showed. (a) and (d) show SIAH-1 expression (detected as in Figure2), (b) and
(e) show Kid/KIF22 expression detected using polyclonal chicken anti-Kid/KIF22 and anti-chicken-FITC as secondary antibody. (c) and (f) are
overlay images of its respective SIAH-1 and Kid/KIF22 expression.
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the same punctuate pattern as we observed in our
results. Other data showed that SIAH-1 was highly
expressed in the nucleus, and that transient expression
of cytoplasmic SIAH-1 resulted in a marked increase in
apoptotic cells in hepatocellular carcinoma cell lines
[26,28]. In addition, inhibition of nuclear SIAH-1
expression resulted in reduced tumor viability and
deregulation of several genes involved in cell cycle regu-
lation. These observations suggested a dual role for
SIAH-1 in hepatocarcinogenesis depending on its
expression level and subcellular localization. High-level
expression in the cytoplasm could be related to tumor
cell apoptosis, whilst reduced expression and nuclear
accumulation correlates with tumor cell proliferation
[26,28]. When other tissues were analyzed we observed
a less systematic variation between normal and tumor
tissues For example in normal lung tissue samples only
very low levels of SIAH-1 were detected, in contrast to
the paired tumoral counterparts which displayed a het-
erogeneous pattern with some cells expressing very high
levels of SIAH-1. These data underline the need to cor-
relate results obtained from tissues extracts with
individual cell expression patterns viewed by
immunochemistry.
SIAH-1 has also been implicated in the cytoplasm-
nuclear translocation of Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), a classic glycolytic enzyme
and multi-functional protein [15]. GAPDH participates
in a recently described cell death cascade in which a
variety of stimuli activate the nitric oxide (NO)
synthases resulting in the S-nitrosylation of GAPDH.
This confers upon it the ability to bind to SIAH-1, and
escort it to the nucleus where SIAH is then able to
degrade key cellular proteins and initiate apoptosis.
Taken together these observations suggest that SIAH-1
could play a similar role in breast carcinoma than in
HHC cells depending on its expression level and sub-
cellular localization.
Kid/KIF22 is a nuclear protein regulated by SIAH-1,
whose level fluctuate in a cell cycle-dependent manner,
increasing during pre-mitotic phases and greatly
decreasing during mitosis [3]. Kid/KIF22 localized to the
nucleus of the interphase cells upon entry into mitosis
on condensed chromosomes and displayed some punc-
tate cytoplasmic staining [21,34]. Interestingly, it was
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Figure 4 SIAH-1 and Kid/KIF22 mRNA expression in paired normal and tumor breast tissues from the same patients. Normal (N) and
tumor (T) tissues from 8 patients representative of the study group are shown with their corresponding SIAH-1 (purple) and Kid/KIF22 (yellow)
mRNA expression levels analyzed by rtPCR.
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G2-M phases. SIAH-1 mediates Kid/KIF22 degradation
via the ubiquitin-proteasome pathway and the balance
between synthesis and degradation of these proteins
influences the correct achievement of mitosis [3]. In the
present study we observed a deregulation of both SIAH-
1 and Kid/KIF22 proteins in tumor breast tissues, chan-
ging from a localized expression to a more diffuse pat-
tern throughout the cell. Kid/KIF22 showed a different
expression pattern in tumors compared to the normal
tissue counterparts. Interestingly, in normal cells the
protein was mostly localized in perinuclear areas whilst
in malignant cells the expression was more diffuse and
the punctuate staining pattern was mostly nuclear, pos-
sibly related to increased mitotic activity of these cells.
In both the normal and tumor tissues we observed a
similar cellular distribution pattern of both SIAH-1 and
Kid/KIF22 staining consistent with previously described
interaction and functional regulation between these two
proteins.
The mRNA level of SIAHs and Kid/KIF22 showed an
important variation among analyzed samples. In samples
f r o mt h es a m ep a t i e n t ,i nm o s tc a s e s ,S I A H - 1m R N A
was down-regulated in tumoral breast tissues compared
to surrounding normal breast tissues. Similar results
about SIAH-1 expression have been reported in hepato-
cellular carcinomas [26,35], indicating that SIAH-1
mRNA expression is frequently reduced in malignant
tissues compared to normal tissues. Matsuo et al.[ 2 6 ]
observed that SIAH-1 was down-regulated in the major-
ity of HCCs analyzed by semiquantitative RT-PCR, and
SIAH-1 was not up-regulated in any of the cancerous
tissues studied. It was also described using semiquantita-
tive RT-PCR that SIAH-1 expression was lower in six
hepatoma cell lines, compared to normal liver tissue
[35]. Our study underlines the importance of relating
the results of gene expression obtained by qRT-PCR to
protein expression and the patterns of subcellular
localization.
Given its structural similarity and possible redundant
function with SIAH-1 we also analyzed the expression
of SIAH-2 mRNA in our samples (data not shown).
A l t h o u g ht h em e d i a no fm R N Ac o p i e so fS I A H - 2w a s
higher in normal than in tumour breast tissues, its
expression was only decreased in half of tumour tissues
compared to its normal counterpart. These different
profiles suggest that pathways implicated in the control
of the expression of these two members of the SIAH
family could be different.
Kid/KIF22 mRNA expression showed also important
differences among the samples. However, more interest-
ing was the observed correlation between Kid/KIF22
mRNA variations between normal and tumor tissues
when compared to SIAH-1 mRNA variations suggesting
an additional regulation step at the level of gene tran-
scription for these two interlinked proteins, in addition
to the previously established mechanisms for protein
stability. Although these data need to be confirmed
using a larger number of samples, they suggest the exis-
tence of mechanisms of co-regulation for these two pro-
teins that deserve to be explored.
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